Prospective evaluation of terazosin for the treatment of autonomic dysreflexia.

Abstract

Terazosin was evaluated in 21 normotensive spinal cord injured patients with autonomic dysreflexia. The patients were followed for 3 months during which the autonomic dysreflexia severity and frequency were evaluated. Autonomic dysreflexia severity mean score was significantly improved when measured at baseline and at 1 week, 1 month and 3 months (10.3 +/- 4.2, 5.08 +/- 2.3, 3.83 +/- 2.5 and 4.5 +/- 1.4, respectively, p < 0.0005). No statistically significant change was seen in erectile function and blood pressure. Three patients complained of fatigue, 1 of whom had the dosage reduced from 5 to 2.5 mg. daily. Terazosin appears to be effective in preventing serious harm from autonomic dysreflexia without erectile function impairment. The effectiveness is significant in the first week and remains for at least 3 months.

• Authors: M B Chancellor, M J Erhard, I H Hirsch, W E Stass Jr
• Journal: The Journal of urology (J Urol) Vol. 151 Issue 1 Pg. 111-3 (Jan 1994) ISSN: 0022-5347 [Print] United States
• PMID: 7902875 (Publication Type: Journal Article)

Chemical References

• Adrenergic alpha-Agonists
• Terazosin
• Prazosin

Topics

• Adrenergic alpha-Agonists (pharmacology, therapeutic use)
• Adult
• Autonomic Nervous System Diseases (drug therapy, etiology)
• Humans
• Male
• Middle Aged
• Prazosin (analogs & derivatives, pharmacology, therapeutic use)
• Prospective Studies
• Reflex, Abnormal (drug effects)
• Severity of Illness Index
• Spinal Cord Injuries (complications)